Investor Presentation

1. Financial Highlights: Revenue rose 8.73% YoY to ₹368.26 Cr for FY25. EBITDA slipped 36.4% to ₹33.87 Cr, with margins down 653 bps to 9.2%. Profit after tax dropped 48.9% to ₹21.12 Cr, pressured by operating challenges and geopolitical issues.

Long-term debt increased to ₹25.34 Cr, short-term debt to ₹47.82 Cr, supporting capacity expansion investments.

Net block stood at ₹142.12 Cr.

Operating cash flow improved to ₹35.82 Cr, balancing ₹34.55 Cr outflow in investing activities.

2. Strategic Initiatives & Growth Drivers: Phase 1 of a ₹160 Cr CAPEX project is now commercialized; Phase 2 targets Q3 FY26 completion despite modest cost overruns.

The Tarapur-based greenfield expansion focuses on capacity ramp-up and regulatory compliance.

The company plans to strengthen its presence in regulated markets to enhance profitability and ease competitive pressure.

3. Business Developments: No new acquisitions or partnerships announced.

The focus remains on internal capacity expansion and improved regulatory compliance aligned with ongoing CAPEX phases.

4. Market Position & Competitive Advantage: NGL Fine-Chem dominates India’s veterinary API market with 95% in-house manufacturing and strong backward integration.

It holds leading market shares (15%-50%) across key products and supplies half of the top 10 global animal healthcare firms.

WHO-GMP and ISO certifications bolster its quality and compliance edge.

5. Investor Implications: Capacity expansions and regulated market focus offer positive growth potential beyond FY26. Elevated debt and geopolitical tensions are execution risks to monitor.

Long-term plans signal a path toward recovery and scaling, making this a key stock to watch for sustained growth.